The biotech mood at the halfway mark of 2018? Bois­ter­ous, fo­cus­ing more at­ten­tion on Chi­na and look­ing for ac­cel­er­at­ed progress

Our End­points 100 group is in a feisty mood here in the sum­mer of 2018.

We asked for their views on some of the biggest head­lines in health­care, and came away with some clear im­pres­sions on how in­dus­try ex­ecs view the lat­est de­vel­op­ments on drug prices, FDA su­per­vi­sion of drug de­vel­op­ment and ap­provals and their com­pa­ny poli­cies re­lat­ed to the con­tro­ver­sial “right-to-try” leg­is­la­tion. We al­so tracked opin­ions on the ex­plo­sion of biotech growth in Chi­na and, as al­ways, mon­i­tored opin­ions on key fi­nan­cial and hir­ing trends for the in­dus­try that af­fect every­one.

We even asked for a re­port card on End­points News con­tent at our sec­ond an­niver­sary. And while we en­joyed some high marks, if you think this crowd was go­ing to let us off with­out a few sharp cri­tiques, well, you don’t know the End­points 100. The one com­mon trait you can ap­ply to all biotech ex­ecs is that they are in­tel­li­gent, ex­treme­ly well ed­u­cat­ed and un­afraid to voice an opin­ion. That goes dou­ble for this group.

Let’s start with their thoughts on the re­cent round of vows by Big Phar­ma to swear off price in­creas­es through the end of the year, which start­ed with a re­ver­sal by Pfiz­er and swift­ly be­came an in­dus­try stan­dard at most of the big play­ers in the in­dus­try.

The drug price freeze may be a cyn­i­cal dodge, but over­all change is com­ing

We gave the 100-plus in our group — with 82 re­spons­es — a chance to score this as a sim­ple dodge by phar­ma to es­cape crit­i­cism, a mean­ing­ful turn­ing point in the in­dus­try or some “oth­er” po­si­tion they could ex­plain.

A slight ma­jor­i­ty, 52%, con­clud­ed it was a sim­ple dodge. An­oth­er 28%, though, see a sig­nif­i­cant in­flec­tion point for bio­phar­ma that shouldn’t be missed. And 20% were some­where else in the mix.

Here’s a sam­pling of opin­ions, which re­flect a more nu­anced col­lec­tion of their thoughts than the sim­ple per­cent­ages may im­ply:

I hate Trump as our Pres­i­dent for MANY rea­sons, but the ac­tions he/Alex Azar are tak­ing will like­ly re­sult in fun­da­men­tal and fa­vor­able changes to bio­phar­ma pric­ing go­ing for­ward. We’re head­ing to­ward a re­bate-less world, which could ac­tu­al­ly cre­ate greater sus­tain­abil­i­ty for in­no­va­tion and need­ed re­wards to at­tract cap­i­tal go­ing for­ward. — Anony­mous

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER